Literature DB >> 27061268

Differential regulation of angiogenesis using degradable VEGF-binding microspheres.

David G Belair1, Michael J Miller2, Shoujian Wang3, Soesiawati R Darjatmoko3, Bernard Y K Binder4, Nader Sheibani5, William L Murphy6.   

Abstract

Vascular endothelial growth factor (VEGF) spatial and temporal activity must be tightly controlled during angiogenesis to form perfusable vasculature in a healing wound. The native extracellular matrix (ECM) regulates growth factor activity locally via sequestering, and researchers have used ECM-mimicking approaches to regulate the activity of VEGF in cell culture and in vivo. However, the impact of dynamic, affinity-mediated growth factor sequestering has not been explored in detail with biomaterials. Here, we sought to modulate VEGF activity dynamically over time using poly(ethylene glycol) microspheres containing VEGF-binding peptides (VBPs) and exhibiting varying degradation rates. The degradation rate of VBP microspheres conferred a differential ability to up- or down-regulate VEGF activity in culture with primary human endothelial cells. VBP microspheres with fast-degrading crosslinks reduced VEGF activity and signaling, while VBP microspheres with no inherent degradability sequestered and promoted VEGF activity in culture with endothelial cells. VBP microspheres with degradable crosslinks significantly reduced neovascularization in vivo, but neither non-degradable VBP microspheres nor bolus delivery of soluble VBP reduced neovascularization. The covalent incorporation of VBP to degradable microspheres was required to reduce neovascularization in a mouse model of choroidal neovascularization in vivo, which demonstrates a potential clinical application of degradable VBP microspheres to reduce pathological angiogenesis. The results herein highlight the ability to modulate the activity of a sequestered growth factor by changing the crosslinker identity within PEG hydrogel microspheres. The insights gained here may instruct the design and translation of affinity-based growth factor sequestering biomaterials for regenerative medicine applications.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Biomimetic microspheres; Choroidal neovascularization; Degradable biomaterials; Endothelial cells; Growth factor sequestering; Vascular endothelial growth factor

Mesh:

Substances:

Year:  2016        PMID: 27061268      PMCID: PMC4866489          DOI: 10.1016/j.biomaterials.2016.03.021

Source DB:  PubMed          Journal:  Biomaterials        ISSN: 0142-9612            Impact factor:   12.479


  60 in total

1.  Microenvironmental VEGF concentration, not total dose, determines a threshold between normal and aberrant angiogenesis.

Authors:  Clare R Ozawa; Andrea Banfi; Nicole L Glazer; Gavin Thurston; Matthew L Springer; Peggy E Kraft; Donald M McDonald; Helen M Blau
Journal:  J Clin Invest       Date:  2004-02       Impact factor: 14.808

2.  VEGF gene delivery to myocardium: deleterious effects of unregulated expression.

Authors:  R J Lee; M L Springer; W E Blanco-Bose; R Shaw; P C Ursell; H M Blau
Journal:  Circulation       Date:  2000-08-22       Impact factor: 29.690

3.  Plasma VEGF and soluble VEGF receptor FLT-1 in proliferative retinopathy: relationship to endothelial dysfunction and laser treatment.

Authors:  P L Lip; F Belgore; A D Blann; M W Hope-Ross; J M Gibson; G Y Lip
Journal:  Invest Ophthalmol Vis Sci       Date:  2000-07       Impact factor: 4.799

4.  Cell-demanded release of VEGF from synthetic, biointeractive cell ingrowth matrices for vascularized tissue growth.

Authors:  Andreas H Zisch; Matthias P Lutolf; Martin Ehrbar; George P Raeber; Simone C Rizzi; Neil Davies; Hugo Schmökel; Deon Bezuidenhout; Valentin Djonov; Peter Zilla; Jeffrey A Hubbell
Journal:  FASEB J       Date:  2003-10-16       Impact factor: 5.191

Review 5.  Biopolymeric delivery matrices for angiogenic growth factors.

Authors:  Andreas H Zisch; Matthias P Lutolf; Jeffrey A Hubbell
Journal:  Cardiovasc Pathol       Date:  2003 Nov-Dec       Impact factor: 2.185

Review 6.  Heparin-protein interactions.

Authors:  Ishan Capila; Robert J Linhardt
Journal:  Angew Chem Int Ed Engl       Date:  2002-02-01       Impact factor: 15.336

7.  Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo.

Authors:  K H Plate; G Breier; H A Weich; W Risau
Journal:  Nature       Date:  1992-10-29       Impact factor: 49.962

8.  Potent inhibition of angiogenesis by D,L-peptides derived from vascular endothelial growth factor receptor 2.

Authors:  Christine Piossek; Karl-Heinz Thierauch; Jens Schneider-Mergener; Rudolf Volkmer-Engert; Martin F Bachmann; Thomas Korff; Hellmut G Augustin; Lothar Germeroth
Journal:  Thromb Haemost       Date:  2003-09       Impact factor: 5.249

9.  VEGF-TRAP(R1R2) suppresses choroidal neovascularization and VEGF-induced breakdown of the blood-retinal barrier.

Authors:  Yoshitsugu Saishin; Yumiko Saishin; Kyoichi Takahashi; Raquel Lima e Silva; Donna Hylton; John S Rudge; Stanley J Wiegand; Peter A Campochiaro
Journal:  J Cell Physiol       Date:  2003-05       Impact factor: 6.384

10.  VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia.

Authors:  Holger Gerhardt; Matthew Golding; Marcus Fruttiger; Christiana Ruhrberg; Andrea Lundkvist; Alexandra Abramsson; Michael Jeltsch; Christopher Mitchell; Kari Alitalo; David Shima; Christer Betsholtz
Journal:  J Cell Biol       Date:  2003-06-16       Impact factor: 10.539

View more
  4 in total

Review 1.  Bioengineering Solutions for Manufacturing Challenges in CAR T Cells.

Authors:  Nicole J Piscopo; Katherine P Mueller; Amritava Das; Peiman Hematti; William L Murphy; Sean P Palecek; Christian M Capitini; Krishanu Saha
Journal:  Biotechnol J       Date:  2017-09-18       Impact factor: 4.677

2.  Antiangiogenic activity of PLGA-Lupeol implants for potential intravitreal applications.

Authors:  Daniel Crístian Ferreira Soares; Diogo Coelho de Paula Oliveira; Luciola Silva Barcelos; Alan Sales Barbosa; Lorena Carla Vieira; Danyelle M Townsend; Domenico Rubello; André Luis Branco de Barros; Lucienir Pains Duarte; Armando Silva-Cunha
Journal:  Biomed Pharmacother       Date:  2017-05-27       Impact factor: 6.529

3.  Human iPSC-derived endothelial cell sprouting assay in synthetic hydrogel arrays.

Authors:  David G Belair; Michael P Schwartz; Thomas Knudsen; William L Murphy
Journal:  Acta Biomater       Date:  2016-05-13       Impact factor: 8.947

4.  Receptor mimicking TGF-β1 binding peptide for targeting TGF-β1 signaling.

Authors:  David G Belair; Jae Sung Lee; Anna V Kellner; Johnny Huard; William L Murphy
Journal:  Biomater Sci       Date:  2021-02-09       Impact factor: 7.590

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.